RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?
Mahale, P., Okhuysen, P. C., & Torres, H. A. (2014). Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?Clinical Gastroenterology and Hepatology, 12(6), 1051-1054.e1. https://doi.org/10.1016/j.cgh.2013.10.034
Authors have reported conflicting results on the persistence of hepatitis C virus (HCV) infection in patients having sustained virologic response (SVR) to treatment. Therefore, we sought to determine whether chemotherapy leads to viral relapse in 30 HCV-infected patients who had SVR before cancer diagnosis. Half of them had hematologic malignancies. Most (60%) received HCV therapy with interferon and ribavirin. Chemotherapy was started at a median of 72 months after SVR and included rituximab (27%), cyclophosphamide (23%), cisplatin (17%), or corticosteroids (37%). No patient had post-SVR viral relapse. Therapeutically induced resolution of HCV appears to be permanent and not affected by chemotherapy.